Sugi Predict

Sugi Predict / Compounds / SCHEMBL16692964

SCHEMBL16692964

SCHEMBL16692964

CC(C)(C)OC(=O)[C@H]1CCC(=O)N1c1cc(Cl)cc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 8/20 0.51
▸ HDAC1 Q13547 7/20 0.51
▸ HDAC8 Q9BY41 7/20 0.51
▸ HDAC5 Q9UQL6 3/20 0.45
▸ CNR2 P34972 7/20 0.42
▸ CYP2C8 P10632 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CNR1 P21554 3/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.38
▸ POLQ O75417 1/20 0.36
▸ P2RX7 Q99572 2/20 0.36
▸ STS P08842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28693724 1.00 HDAC6 (0.51) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL16691761 0.85 ALDH1A1 (0.47) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL16681072 0.85 ALDH1A1 (0.47) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL16691755 0.85 HDAC1 (0.46) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL28642152 0.83 FFAR4 (0.44) CNR2CYP2C8CYP2C9CYP2C19CNR1
SCHEMBL28642151 0.83 FFAR4 (0.44) CNR2CYP2C8CYP2C9CYP2C19CNR1
SCHEMBL2568950 0.78 SMN1; SMN2 (0.50) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL2568946 0.78 SMN1; SMN2 (0.50) HDAC6HDAC1HDAC8HDAC5CNR2
SCHEMBL16765157 0.78 FFAR4 (0.38) HDAC6HDAC1HDAC8FFAR4STS
SCHEMBL16765156 0.78 FFAR4 (0.38) HDAC6HDAC1HDAC8FFAR4STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417389-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-12-19 — — US disclosed
US-20230174511-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. (US) 2023-06-08 — — US disclosed
US-20230174511-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. (US) 2023-06-08 — — US disclosed
CN-109305959-B Pyrimidinyl tyrosine kinase inhibitors 比奥根MA公司 2022-02-08 — — CN disclosed
US-20210017155-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2021-01-21 — — US disclosed
EP-3753934-A1 PYRIMIDINYL DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS Biogen MA Inc. (US) 2020-12-23 — — EP disclosed
EP-3385263-B1 PYRIMIDINYL TYROSINE KINASE INHIBITORS BIOGEN MA INC (US) 2020-07-22 — — EP disclosed
US-10618887-B2 Pyrimidinyl tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-04-14 — — US disclosed
US-20190047986-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2019-02-14 — — US disclosed
US-10189817-B2 Inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2019-01-29 — — US disclosed
US-9944622-B2 Pyrimidinyl tyrosine kinase inhibitors BIOGEN MA INC. (US) 2018-04-17 — — US disclosed
US-20170114039-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN IDEC MA INC. 2017-04-27 — — US disclosed
US-20160304494-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-10-20 — — US disclosed
US-20160304494-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-10-20 — — US disclosed
US-9394277-B2 Pyrimidinyl tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-07-19 — — US disclosed
US-9394277-B2 Pyrimidinyl tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-07-19 — — US disclosed
US-9353087-B2 Inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2016-05-31 — — US disclosed
US-20150158843-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2015-06-11 — — US disclosed
US-20150158843-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2015-06-11 — — US disclosed
US-20150126528-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2015-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017155-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885
US-20240417389-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885
US-20150126528-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN HDAC6 1626/4885HDAC1 1993/4885HDAC8 2342/4885
US-20170114039-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN HDAC6 1626/4885HDAC1 1993/4885HDAC8 2342/4885
US-10189817-B2 Inhibitors of Bruton's tyrosine kinase ABL1, BTK, LYN HDAC6 1626/4885HDAC1 1993/4885HDAC8 2342/4885
US-20230174511-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2400/4885HDAC1 3317/4885HDAC8 3070/4885
US-20150158843-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885
US-20190047986-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885
US-20160304494-A1 PYRIMIDINYL TYROSINE KINASE INHIBITORS ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885
US-10618887-B2 Pyrimidinyl tyrosine kinase inhibitors ABL1, BTK, ABL2 HDAC6 2552/4885HDAC1 3370/4885HDAC8 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.